Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Diagnostic and Statistical Manual of Mental Disorders
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_5485 · Cited by 10,169
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986 · cited 3×
“5, GDS score = 3 [38] and clinically recognizable memory impairment without fulfilling either the DSM-IV [1] or NINCDS-ADRDA (8) criteria for dementia and AD.”
BackgroundMethodCurrent concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781 · cited 1×
“Recent studies using T-tau and Aβ42 show that future AD can be accurately predicted in the MCI stage, which is considered by many as a prodromal stage of AD [5,32].”
ResultBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“Although several studies show that the use of CSF T-tau/Aβ42 or Aβ42/Aβ40 ratios yield good AD diagnostic accuracy [2,17,23,26,31] and MCI-AD prediction effects [16,20], it is usually not reported if the ratio statistically increments the prediction accuracy over the univariate measures.”
MethodResultSelf-citationNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“Our results confirm that before the onset of clinically overt AD, there are changes in the CSF biochemical composition that reflect AD pathology: neurofibrillary tangles, amyloid plaques [4,36], and oxidative damage to neuronal cell membranes [30,36].”
Result
Cited by
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationAlzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2007) · Advances in Behavioral Biology · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,468
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Self-citationEwers, M., Walsh, C., Trojanowski, J. Q., Shaw, L. M., Petersen, R. C., Jack, C. R., Feldman, H. H., Bokde, A. L. W., Alexander, G. E., Scheltens, P., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.019 · Cited by 394
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
Self-citationBrain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306
“…of cognitive change and do not drop more over time; CSF tau concentrations are more dynamic over the course of MCI and AD and changes correlate to some extent with cognitive decline; and tau changes correlate better with acknowledged late-appearing biomarkers such as hippocampal atrophy [90 – 94].”
BackgroundBiochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.013 · Cited by 284
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Rossini, P. M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A. C., Cappa, S. F., Escudero, J., Fraga, F. J., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.03.003 · Cited by 233
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“Recent studies also show an increase in F2-isoprostanes in MCI cases with prodromal AD (Brys et al. 2009a) and in asymptomatic carriers of FAD mutations (Ringman et al. 2008).”
BackgroundSelf-citationMaia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
de Souza, L. C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., De Paz, R., Dubois, B., & Sarazin, M. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.207183 · Cited by 193
“The CSF biomarkers total tau (T-tau), phosphorylated tau (P-tau) and beta-amyloid peptide 1-42 (Aβ42) can distinguish controls from AD subjects [1, 2], even in early stages of the disease [3-8].”
Obstructive sleep apnea and longitudinal Alzheimer’s disease biomarker changes
Bubu, O. M., Pirraglia, E., Andrade, A. G., Sharma, R. A., Gimenez-Badia, S., Umasabor-Bubu, O. Q., Hogan, M. M., Shim, A. M., Mukhtar, F., Sharma, N., et al. (2019) · Sleep · doi:10.1093/sleep/zsz048 · Cited by 164
“Positron emission tomography (PET) amyloid tracer uptake and decreases in cerebrospinal fluid (CSF) amyloid-beta42 (A β 42) levels are robust predictors of amyloid burden as well as of future development of AD [8, 9].”
Self-citationRitchie, C., Smailagic, N., Noel-Storr, A. H., Takwoingi, Y., Flicker, L., Mason, S. E., & McShane, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008782.pub4 · Cited by 159
Biomarkers in translational research of Alzheimer’s Disease
Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67
“Several studies addressing the utility of CSF markers in predicting the risk of progression from MCI to AD suggest that increased levels of tau, p-tau, and decreased levels of Aβ42 are present in MCI (Brys et al., 2009), with a sensitivity that is comparable to that seen in more advanced AD.”
BackgroundResultInfluentialMosconi, L., Glodzik, L., Mistur, R., McHugh, P., Rich, K. E., Javier, E., Williams, S., Pirraglia, E., De Santi, S., Mehta, P. D., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.011 · Cited by 46
“As several studies reported that the ratio of Aβ42 to Aβ40 is superior to the concentration of either measure individually in discriminating AD from controls and from other dementias (15,20), Aβ42/40 ratios were created and compared across groups.”
BackgroundSelf-citationProgress and challenges in the diagnosis of dementia: a critical review
Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31
Metadata
- Authors
- Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., Glodzik-Sobanska, L., De Santi, S., Zinkowski, R., Mehta, P., Pratico, D., Saint Louis, L. A., Wallin, A., Blennow, K., & de Leon, M. J.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 30
- Issue
- 5
- Pages
- 682-690
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W1979121852
- Cited by
- 185
- References
- 44
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.